UTRS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 20:18):

Stats
Šios dienos apimtis	26 100.00
Vidutinė apimtis	2 209.00
Rinkos kapitalizacija	8 879.00
EPS	$0 ( 2024-04-29 )
Kita pelno data	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-01	Cohen Daniel	Buy	0	Common Stock
2023-02-09	New Enterprise Associates 13 Lp	Buy	24 437 927	Common Stock
2023-02-09	Accelmed Partners Ii L.p.	Sell	0	Common Stock
2023-02-09	Geiger Uri	Buy	0	Common Stock
2023-01-02	Usen Todd	Buy	0

INSIDER POWER
100.00
Last 92 transactions
Buy: 38 540 336 \| Sell: 1 194 556

Minerva Surgical, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TLGT	0.867
HOWL	0.865
SVAC	0.852
GOODM	0.851
IVA	0.844
NLTX	0.841
MTSL	0.839
VINC	0.839
NVFY	0.837
NSTG	0.833

10 Labiausiai neigiamai susiję koreliacijos
AMRB	-0.912
LWAC	-0.884
SRAC	-0.841
NETE	-0.831
FLMN	-0.827
LMRKN	-0.822
MMAC	-0.813

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Minerva Surgical, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$50.29M
Bruto pelnas:	$27.24M (54.17 %)
EPS:	$-23.68

FY	2022
Pajamos:	$50.29M
Bruto pelnas:	$27.24M (54.17 %)
EPS:	$-23.68

FY	2021
Pajamos:	$52.10M
Bruto pelnas:	$30.52M (58.58 %)
EPS:	$-1.158

FY	2020
Pajamos:	$37.77M
Bruto pelnas:	$19.12M (50.62 %)
EPS:	$-1.090

Financial Reports:

No articles found.

Minerva Surgical, Inc.

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.